TD Asset Management Inc Has $3.84 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

TD Asset Management Inc increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 14.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 178,164 shares of the biotechnology company’s stock after buying an additional 23,000 shares during the period. TD Asset Management Inc owned 0.20% of Rocket Pharmaceuticals worth $3,836,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in Rocket Pharmaceuticals by 5.2% during the second quarter. Rhumbline Advisers now owns 101,134 shares of the biotechnology company’s stock worth $2,177,000 after buying an additional 4,958 shares during the last quarter. Privium Fund Management B.V. increased its holdings in Rocket Pharmaceuticals by 6.8% during the second quarter. Privium Fund Management B.V. now owns 250,980 shares of the biotechnology company’s stock worth $4,964,000 after buying an additional 15,930 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Rocket Pharmaceuticals by 30.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,092 shares of the biotechnology company’s stock worth $368,000 after buying an additional 3,995 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Rocket Pharmaceuticals by 10.4% during the second quarter. Bank of New York Mellon Corp now owns 239,877 shares of the biotechnology company’s stock worth $5,165,000 after buying an additional 22,521 shares during the last quarter. Finally, EFG Asset Management North America Corp. increased its holdings in Rocket Pharmaceuticals by 47.0% during the second quarter. EFG Asset Management North America Corp. now owns 222,046 shares of the biotechnology company’s stock worth $4,780,000 after buying an additional 71,044 shares during the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Mark Andrew White sold 3,026 shares of the company’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $20.39, for a total transaction of $61,700.14. Following the completion of the sale, the insider now owns 72,220 shares of the company’s stock, valued at $1,472,565.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 31.10% of the stock is currently owned by company insiders.

Rocket Pharmaceuticals Trading Down 2.9 %

Shares of Rocket Pharmaceuticals stock opened at $19.03 on Thursday. The firm has a 50-day moving average of $20.75 and a 200-day moving average of $22.98. The stock has a market cap of $1.73 billion, a PE ratio of -6.63 and a beta of 1.10. Rocket Pharmaceuticals, Inc. has a 52-week low of $15.27 and a 52-week high of $32.53. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.79 and a current ratio of 7.79.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.02). During the same period last year, the company earned ($0.82) EPS. As a group, sell-side analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.97 EPS for the current year.

Analyst Ratings Changes

RCKT has been the topic of several research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. Canaccord Genuity Group decreased their price objective on shares of Rocket Pharmaceuticals from $49.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, July 3rd. Chardan Capital reiterated a “buy” rating and issued a $62.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. JPMorgan Chase & Co. upped their price objective on shares of Rocket Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.75.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.